Evofem Biosciences to Present at Aegis Virtual Conference on Wednesday, February 23, 2022


SAN DIEGO, Feb. 8, 2022 /PRNewswire/ -- Evofem Biosciences Inc., (NASDAQ: EVFM) will present at the Aegis Virtual Conference as follows:


Wednesday, February 23, 2022 


4:30 p.m. ET (1:30 p.m. PT)

Access Webcast:

https://evofem.investorroom.com/Aegis2022 or


Add to Calendar:

iCalendar (.ics) file

About Evofem Biosciences
Evofem Biosciences, Inc., (NASDAQ: EVFM) is developing and commercializing innovative products to address unmet needs in women's sexual and reproductive health, including hormone-free, woman-controlled contraception and protection from certain sexually transmitted infections (chlamydia and gonorrhea). The Company's first FDA-approved product, Phexxi® (lactic acid, citric acid and potassium bitartrate), is a hormone-free, on-demand prescription contraceptive vaginal gel. It comes in a box of 12 pre-filled applicators and is applied 0-60 minutes before each act of sex. Learn more at phexxi.com and evofem.com.

Phexxi® is a registered trademark of Evofem Biosciences, Inc.

Investor Relations Contact
Amy Raskopf
Evofem Biosciences, Inc.
Mobile: (917) 673-5775



Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/evofem-biosciences-to-present-at-aegis-virtual-conference-on-wednesday-february-23-2022-301477311.html

SOURCE Evofem Biosciences, Inc.

Company Codes: NASDAQ-NMS:EVFM

Back to news